Imetelstat and Canakinumab in Lower-Risk MDS

Opinion
Video

Drs Safah and Koprivinikar discuss emerging therapies, such as imetelstat and canakinumab, and where they might fit in the treatment paradigm for lower-risk MDS.

Related Videos
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Gary J. Schiller, MD, an expert on MDS
Related Content